Last reviewed · How we verify
PD-1 combined with chemotherapy
PD-1 inhibitor combined with chemotherapy blocks immune checkpoint PD-1 to restore anti-tumor T-cell activity while chemotherapy directly kills cancer cells.
PD-1 inhibitor combined with chemotherapy blocks immune checkpoint PD-1 to restore anti-tumor immunity while chemotherapy directly kills cancer cells. Used for Advanced or metastatic solid tumors (specific indication not specified by institution).
At a glance
| Generic name | PD-1 combined with chemotherapy |
|---|---|
| Also known as | PD-1 combined with chemotherapy group |
| Sponsor | Shandong Provincial Hospital |
| Drug class | PD-1 inhibitor + chemotherapy combination |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
PD-1 inhibitors release the brakes on the immune system by blocking the PD-1/PD-L1 interaction, allowing T cells to recognize and attack cancer cells. When combined with chemotherapy, the chemotherapy agent provides direct cytotoxic effects against tumors while simultaneously enhancing immunogenicity, creating a synergistic anti-tumor response. This combination approach is designed to improve overall survival and response rates compared to either modality alone.
Approved indications
- Advanced or metastatic solid tumors (specific indication dependent on the chemotherapy partner and clinical trial data)
Common side effects
- Fatigue
- Nausea and vomiting
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Myelosuppression
- Peripheral neuropathy
Key clinical trials
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (PHASE3)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD-1 combined with chemotherapy CI brief — competitive landscape report
- PD-1 combined with chemotherapy updates RSS · CI watch RSS
- Shandong Provincial Hospital portfolio CI